Robert L. Coleman, MD, FACOG, FACS, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.
Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the results of the phase III VELIA trial in patients with advanced ovarian cancer.
Data from the phase III trial were presented at the 2019 ESMO Congress and demonstrated that the frontline combination of veliparib and chemotherapy followed by veliparib maintenance led to a significant improvement in progression-free survival (PFS) versus chemotherapy and placebo followed by placebo maintenance among patients with newly diagnosed, metastatic ovarian cancer.
The regimen was evaluated among the overall population, patients with germline and somaticBRCAmutations, and those with homologous recombination deficiency (HRD), says Coleman. Among patients with BRCA
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
Responders to UGN-101 Have Positive RFS in Upper Tract Urothelial Cancer
May 5th 2024In patients at 15 centers who had upper tract urothelial cancer, those with no evidence of disease after UGN-101 induction had a 68% rate of 3-year recurrence-free survival, and this outcome did not differ based on tumor status, method of instillation, or treatment intent.
Read More